Skandinaviska Enskilda Banken AB publ Has $14.02 Million Stake in IDEXX Laboratories, Inc. $IDXX

Skandinaviska Enskilda Banken AB publ reduced its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 5.9% during the 3rd quarter, HoldingsChannel reports. The firm owned 21,949 shares of the company’s stock after selling 1,386 shares during the quarter. Skandinaviska Enskilda Banken AB publ’s holdings in IDEXX Laboratories were worth $14,023,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in the business. Glenview Trust Co grew its holdings in IDEXX Laboratories by 6.0% in the 3rd quarter. Glenview Trust Co now owns 40,729 shares of the company’s stock valued at $26,021,000 after buying an additional 2,312 shares during the last quarter. Zions Bancorporation National Association UT grew its stake in shares of IDEXX Laboratories by 125.5% in the third quarter. Zions Bancorporation National Association UT now owns 345 shares of the company’s stock worth $220,000 after acquiring an additional 192 shares during the last quarter. Vanguard Group Inc. increased its position in IDEXX Laboratories by 0.9% during the third quarter. Vanguard Group Inc. now owns 9,962,025 shares of the company’s stock worth $6,364,638,000 after acquiring an additional 86,040 shares during the period. Fifth Third Bancorp raised its stake in IDEXX Laboratories by 23.3% during the 3rd quarter. Fifth Third Bancorp now owns 7,374 shares of the company’s stock valued at $4,711,000 after purchasing an additional 1,392 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in IDEXX Laboratories by 60.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 869,930 shares of the company’s stock valued at $555,802,000 after purchasing an additional 326,348 shares during the period. Institutional investors own 87.84% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on IDXX. BTIG Research reduced their target price on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a research note on Tuesday, February 3rd. Jefferies Financial Group reiterated a “buy” rating and issued a $830.00 price objective on shares of IDEXX Laboratories in a research report on Tuesday, November 4th. Piper Sandler lowered their price objective on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a research report on Monday, February 9th. Weiss Ratings lowered IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, January 29th. Finally, Barclays decreased their price target on shares of IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. Seven analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $783.33.

IDEXX Laboratories Stock Up 1.4%

Shares of NASDAQ:IDXX opened at $634.90 on Thursday. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $769.98. The firm has a market cap of $50.70 billion, a P/E ratio of 48.58, a P/E/G ratio of 3.81 and a beta of 1.67. The company has a quick ratio of 0.90, a current ratio of 1.23 and a debt-to-equity ratio of 0.23. The company’s 50-day moving average price is $680.64 and its two-hundred day moving average price is $669.42.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Monday, February 2nd. The company reported $2.92 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.93 by ($0.01). The firm had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. IDEXX Laboratories’s revenue was up 14.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.53 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. As a group, research analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, EVP George Fennell sold 11,345 shares of the firm’s stock in a transaction dated Tuesday, February 10th. The stock was sold at an average price of $646.72, for a total transaction of $7,337,038.40. Following the transaction, the executive vice president owned 9,823 shares in the company, valued at approximately $6,352,730.56. This trade represents a 53.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.98% of the stock is currently owned by company insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.